Genetic variation in populations from central Argentina based on mitochondrial and Y chromosome DNA evidence.

J Hum Genet

Instituto de Antropología de Córdoba (IDACOR), CONICET/Universidad Nacional de Córdoba, 5000, Córdoba, Argentina.

Published: April 2018

We present new data and analysis on the genetic variation of contemporary inhabitants of central Argentina, including a total of 812 unrelated individuals from 20 populations. Our goal was to bring new elements for understanding micro-evolutionary and historical processes that generated the genetic diversity of the region, using molecular markers of uniparental inheritance (mitochondrial DNA and Y chromosome). Almost 76% of the individuals show mitochondrial lineages of American origin. The Native American haplogroups predominate in all surveyed localities, except in one. The larger presence of Eurasian maternal lineages were observed in the plains (Pampas) of the southeast, whereas the African lineages are more frequent in northern Córdoba. On the other hand, the analysis of 258 male samples reveals that 92% of them present Eurasian paternal lineages, 7% carry Native American haplogroups, and only 1% of the males show African lineages. The maternal lineages have high genetic diversity homogeneously distributed throughout central Argentina, probably as result of a recent common origin and sustained gene flow. Migratory events that occurred in colonial and recent times should have contributed to hiding any traces of differentiation that might have existed in the past. The analysis of paternal lineages showed also homogeneous distribution of the variation together with a drastic reduction of the native male population.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s10038-017-0406-7DOI Listing

Publication Analysis

Top Keywords

central argentina
12
genetic variation
8
genetic diversity
8
native american
8
american haplogroups
8
maternal lineages
8
african lineages
8
paternal lineages
8
lineages
7
genetic
4

Similar Publications

Background: Prodromal stage of Lewy Body Dementia (LBD) is characterized by a set of symptoms that do not yet meet the criteria for dementia. These symptoms are caused by changes in the brain that have not yet reached the threshold for triggering the disease in its complete form. Identifying the prodromal stage of neurodegenerative diseases is crucial for early treatment and prevention of progression to a clinical stage.

View Article and Find Full Text PDF

Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial.

Obstet Gynecol

January 2025

Children's Hospital Colorado, Aurora, Colorado; Vaccine Research and Development, Pfizer Inc, Pearl River, New York; the South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit and Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, and Famcru, Department of Paediatrics and Child Health, University of Stellenbosch, and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, SA-MRC Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa; Vaccines and Immunity Team, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, the Gambia; Institute for International Health Charité, Universitätsmedizin, Berlin, Germany; Vaccine Research and Development, Pfizer Ltd, Marlow, United Kingdom; Instituto de Maternidad y Ginecología Nuestra Señora de Las Mercedes, San Miguel de Tucumán, and iTrials-Hospital Militar Central and iTrials, Buenos Aires, Argentina; Clinical Research Prime, Idaho Falls, Idaho; Boeson Research, Missoula, Montana; Meridian Clinical Research, Hastings, Nebraska; Asian Hospital and Medical Center, Manila, the Philippines; Department of Pediatrics, Spaarne Gasthuis, Haarlem and Hoofddorp, the Department of Pediatrics, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, and the ReSViNET Foundation, Zeist, the Netherlands; Meilahti Vaccine Research Center MeVac, Inflammation Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; National Taiwan University Hospital, Taipei, Taiwan; the Department of Obstetrics and Gynecology, Sendai City Hospital, Sendai, Japan; Institute of Biomedical Sciences, University of Chile School of Medicine, Santiago, Chile; University of Otago and New Zealand Clinical Research, Christchurch, New Zealand; CHU Sainte-Justine, Montreal, Quebec, Canada; Hospital Moinhos de Vento and Pontifícia Universidade Católica RGS, Porto Alegre, Brazil; the Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; Arké SMO S.A. de C.V., Mexico City, Mexico; University of Western Australia School of Medicine, Vaccine Trials Group, Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, and Perth Children's Hospital, Nedlands, Western Australia, and Vaccine Clinical Research, Pfizer Inc, Sydney, Australia; and Worldwide Safety, Pfizer Srl, Milan, Italy.

Objective: To evaluate descriptive efficacy data, exploratory immunogenicity data, and safety follow-up through study completion from the global, phase 3 MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal vaccination trial of bivalent respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVpreF).

Methods: MATISSE was a phase 3, randomized, double-blinded, placebo-controlled trial. Healthy pregnant participants aged 49 years or younger at 24-36 weeks of gestation were randomized (1:1) to receive a single RSVpreF 120 micrograms or placebo dose.

View Article and Find Full Text PDF

Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine.

Obstet Gynecol

January 2025

South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit and the Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, SA-MRC Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa; the Vaccines and Immunity Team, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, the Gambia; the Institute for International Health Charité, Universitätsmedizin, Berlin, Germany; Children's Hospital Colorado, Aurora, Colorado; Vaccine Research and Development, Pfizer Inc, Pearl River, New York; Vaccine Research and Development, Pfizer Inc, Hurley, United Kingdom; Instituto de Maternidad y Ginecología Nuestra Señora de Las Mercedes, San Miguel de Tucumán, Argentina; iTrials-Hospital Militar Central, Buenos Aires, Argentina; the Stanford University School of Medicine, Palo Alto, California; the Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington; and Worldwide Safety, Pfizer Srl, Milan, Italy.

Objective: To describe preterm birth frequency and newborn and infant outcomes overall and among preterm children in the MATISSE (Maternal Immunization Study for Safety and Efficacy) trial of maternal vaccination with bivalent respiratory syncytial virus (RSV) prefusion F protein-based vaccine (RSVpreF) to protect infants against severe RSV-associated illness.

Methods: MATISSE was a global, phase 3, randomized, double-blind trial. Pregnant individuals received single injections of RSVpreF or placebo.

View Article and Find Full Text PDF

In clinics, physical injuries to the spinal cord cause a temporary motor areflexia below lesion, known as spinal shock. This topic is still underexplored due to the lack of preclinical spinal cord injury (SCI) models that do not use anesthesia, which would affect spinal excitability. Our innovative design considered a custom-made micro impactor that provides localized and calibrated strikes to the ventral surface of the thoracic spinal cord of the entire CNS isolated from neonatal rats.

View Article and Find Full Text PDF

This collaborative work by over 180 researchers from 40+ countries addresses the challenges posed by "phantom agents"-putative pathogenic agents named in literature without supporting data on their existence. Those agents remain on regulatory lists, creating barriers in trade and plant certification. Historically identified based solely on symptoms, these agents lack isolates or sequence data, making reliable detection or risk assessment impossible.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!